JP2016501020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501020A5 JP2016501020A5 JP2015544499A JP2015544499A JP2016501020A5 JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5 JP 2015544499 A JP2015544499 A JP 2015544499A JP 2015544499 A JP2015544499 A JP 2015544499A JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- seq
- virus
- influenza
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 49
- 241000712431 Influenza A virus Species 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 29
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 229940024606 amino acid Drugs 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 26
- 206010022000 influenza Diseases 0.000 claims description 24
- 241000712461 unidentified influenza virus Species 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 17
- 208000037797 influenza A Diseases 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 229960001230 asparagine Drugs 0.000 claims description 8
- 235000009582 asparagine Nutrition 0.000 claims description 8
- 235000003704 aspartic acid Nutrition 0.000 claims description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
- 108091034135 Vault RNA Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000003501 vero cell Anatomy 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 210000000991 chicken egg Anatomy 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
- 239000000277 virosome Substances 0.000 claims description 2
- 229940126581 whole-virion vaccine Drugs 0.000 claims description 2
- 241000894007 species Species 0.000 claims 1
- 241000702620 H-1 parvovirus Species 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732809P | 2012-12-03 | 2012-12-03 | |
| US61/732,809 | 2012-12-03 | ||
| PCT/EP2013/075294 WO2014086732A2 (en) | 2012-12-03 | 2013-12-02 | Influenza virus reassortment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501020A JP2016501020A (ja) | 2016-01-18 |
| JP2016501020A5 true JP2016501020A5 (enExample) | 2017-01-19 |
| JP6421128B2 JP6421128B2 (ja) | 2018-11-07 |
Family
ID=49713076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544499A Active JP6421128B2 (ja) | 2012-12-03 | 2013-12-02 | リアソータントインフルエンザａウイルス |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9708585B2 (enExample) |
| EP (1) | EP2925356A2 (enExample) |
| JP (1) | JP6421128B2 (enExample) |
| KR (1) | KR20150110494A (enExample) |
| CN (1) | CN105120893B (enExample) |
| AU (2) | AU2013354219A1 (enExample) |
| BR (1) | BR112015012380A2 (enExample) |
| CA (1) | CA2893429A1 (enExample) |
| HK (1) | HK1214959A1 (enExample) |
| MX (1) | MX2015006927A (enExample) |
| WO (1) | WO2014086732A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708585B2 (en) * | 2012-12-03 | 2017-07-18 | Seqirus UK Limited | Influenza virus reassortment |
| US10323231B2 (en) * | 2015-04-24 | 2019-06-18 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
| JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
| GB201602535D0 (en) * | 2016-02-12 | 2016-03-30 | Univ Edinburgh | Improved flu vaccine yield |
| AU2018326931B2 (en) * | 2017-08-28 | 2024-07-25 | The Research Foundation For Microbial Diseases Of Osaka University | Method for gradual construction of reassortant influenza virus |
| AU2018357917B2 (en) | 2017-10-30 | 2024-08-01 | Takeda Pharmaceutical Company Limited | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| US12239699B2 (en) * | 2018-09-11 | 2025-03-04 | Shanghai Public Health Clinical Center | Immunogen for broad-spectrum influenza vaccine and application thereof |
| KR101954904B1 (ko) | 2018-10-15 | 2019-03-06 | 남종규 | 복층의 태양광 설치 구조 |
| CN111647610B (zh) * | 2020-06-02 | 2021-09-03 | 扬州大学 | 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| CA2334857C (en) | 1998-06-12 | 2012-03-20 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
| CA2383105C (en) | 1999-09-24 | 2010-01-26 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| AU3604201A (en) | 2000-03-03 | 2001-09-12 | Chemo Sero Therapeut Res Inst | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| CA2438960A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
| ATE503493T1 (de) | 2001-02-23 | 2011-04-15 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| DK1742659T3 (da) | 2004-04-05 | 2013-06-03 | Zoetis P Llc | Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| US20080254067A1 (en) | 2004-05-20 | 2008-10-16 | Id Biomedical Corporation | Process for the Production of an Influenza Vaccine |
| AU2005322353B2 (en) | 2004-12-23 | 2011-09-01 | Medimmune, Llc | Non-tumorigenic MDCK cell line for propagating viruses |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| CA2613283A1 (en) | 2005-06-21 | 2007-01-04 | Medimmune Vaccines, Inc. | Methods and compositions for expressing a heterologous protease |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| JP5602366B2 (ja) | 2005-11-01 | 2014-10-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| BRPI0618254A2 (pt) | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| WO2007126810A2 (en) * | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| DK2016194T3 (en) | 2006-04-19 | 2015-06-15 | Medimmune Llc | METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS |
| HRP20130023T1 (hr) | 2006-10-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | Cjepivo koje sadrži emulziju ulje u vodi kao adjuvans |
| AU2007330494B2 (en) | 2006-12-06 | 2014-03-13 | Seqirus UK Limited | Vaccines including antigen from four strains of influenza virus |
| WO2008157419A2 (en) * | 2007-06-13 | 2008-12-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| JP5686741B2 (ja) * | 2008-12-16 | 2015-03-18 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | インフルエンザワクチンの生成 |
| EP2233152A1 (en) * | 2009-03-24 | 2010-09-29 | Avir Green Hills Biotechnology Research Development Trade Ag | High growth reassortant influenza A virus |
| EP2401384B1 (en) | 2009-05-21 | 2012-10-03 | Novartis AG | Reverse genetics using non-endogenous pol i promoters |
| AU2010266078B2 (en) * | 2009-06-25 | 2014-08-14 | Medimmune, Llc | Swine influenza hemagglutinin variants |
| JP2013500712A (ja) | 2009-07-31 | 2013-01-10 | ノバルティス アーゲー | 逆遺伝学系 |
| US8945904B2 (en) | 2010-05-21 | 2015-02-03 | Novartis Ag | Influenza virus reassortment |
| FR2962739B1 (fr) * | 2010-07-13 | 2014-01-31 | Univ Claude Bernard Lyon | Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza |
| US9708585B2 (en) * | 2012-12-03 | 2017-07-18 | Seqirus UK Limited | Influenza virus reassortment |
-
2013
- 2013-12-02 US US14/648,886 patent/US9708585B2/en active Active
- 2013-12-02 HK HK16102968.6A patent/HK1214959A1/zh unknown
- 2013-12-02 WO PCT/EP2013/075294 patent/WO2014086732A2/en not_active Ceased
- 2013-12-02 EP EP13799527.0A patent/EP2925356A2/en not_active Withdrawn
- 2013-12-02 CN CN201380071503.1A patent/CN105120893B/zh active Active
- 2013-12-02 MX MX2015006927A patent/MX2015006927A/es unknown
- 2013-12-02 CA CA2893429A patent/CA2893429A1/en not_active Abandoned
- 2013-12-02 BR BR112015012380A patent/BR112015012380A2/pt not_active IP Right Cessation
- 2013-12-02 JP JP2015544499A patent/JP6421128B2/ja active Active
- 2013-12-02 KR KR1020157016758A patent/KR20150110494A/ko not_active Ceased
- 2013-12-02 AU AU2013354219A patent/AU2013354219A1/en not_active Abandoned
-
2017
- 2017-06-13 US US15/621,270 patent/US10500266B2/en active Active
-
2018
- 2018-09-19 AU AU2018232956A patent/AU2018232956B2/en active Active
-
2019
- 2019-10-28 US US16/665,104 patent/US20200155666A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501020A5 (enExample) | ||
| JP2016509864A5 (enExample) | ||
| JP2015119730A5 (enExample) | ||
| Milián et al. | Current and emerging cell culture manufacturing technologies for influenza vaccines | |
| Cauldwell et al. | Viral determinants of influenza A virus host range | |
| Zhou et al. | Characterization of uncultivable bat influenza virus using a replicative synthetic virus | |
| Horimoto et al. | Enhanced growth of seed viruses for H5N1 influenza vaccines | |
| Bissinger et al. | Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production | |
| JP2019011344A5 (enExample) | ||
| Chen et al. | The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response | |
| Feng et al. | Equine and canine influenza H3N8 viruses show minimal biological differences despite phylogenetic divergence | |
| Petiot et al. | Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17 | |
| JP2012511914A5 (enExample) | ||
| Jang et al. | Principles underlying rational design of live attenuated influenza vaccines | |
| JP2013179943A5 (enExample) | ||
| WO2008156681A2 (en) | Adenoviral vectors for influenza virus production | |
| Neumann et al. | Identification of amino acid changes that may have been critical for the genesis of A (H7N9) influenza viruses | |
| Li et al. | Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome | |
| Abdoli et al. | Comparison between MDCK and MDCK-SIAT1 cell lines as preferred host for cell culture-based influenza vaccine production | |
| Johnson et al. | Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs | |
| Silva et al. | Recent advances and current challenges in process intensification of cell culture‐based influenza virus vaccine manufacturing | |
| Mostafa et al. | Efficient generation of recombinant influenza a viruses employing a new approach to overcome the genetic instability of HA segments | |
| Mostafa et al. | The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs | |
| CN104195154A (zh) | 新城疫病毒Mukteswar中等毒力疫苗株反向遗传操作系统及其应用 | |
| Zhou et al. | High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1 |